Press releases | Medtronic

Month Year

Email alerts

Your search returned 108 results

Oct 1, 2020

Medtronic Resolute Onyx™ Drug Eluting Stent (DES) First to Receive One-Month DAPT Labeling in the U.S. with Expanded Indication for High Bleeding Risk Patients

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy...
Jun 25, 2020

New Real-World Data from Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure in Patients with Hypertension Out to Three Years

Regardless of the Number of Anti-Hypertensive Medications Prescribed, Majority of Patients with Highest BP Showed Significant Drops at Three Years

DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today reported new data from the Global SYMPLICITY Registry (GSR), which showed that...
Jun 5, 2020

Medtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe

DUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual...
May 18, 2020

Jeffrey J. Popma, M.D. to Join Medtronic as Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart Businesses

DUBLIN, May 18, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School...
Mar 30, 2020

Medtronic Onyx ONE Clear Study of One-Month Dual-Antiplatelet Therapy in High Bleeding Risk Stent Patients Beats Performance Goal

First Study in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DES

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR)...
Mar 29, 2020

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication

DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial....
Feb 4, 2020

Medtronic Begins New Pilot Study as Part of SPYRAL HTN Clinical Program for Renal Denervation in Hypertension Patients

SPYRAL DYSTAL Study to Evaluate the Effects of RDN Using Fewer, Targeted Ablations to Achieve Meaningful Blood Pressure Reductions

DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity™ Spyral renal...
Oct 21, 2019

Sean Salmon Named Executive Vice President and Group President of Medtronic Diabetes

DUBLIN, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced that Sean Salmon, previously Senior Vice President (SVP) and President, Coronary and Structural Heart (CSH)...
Sep 26, 2019

Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

TCT19: First Results from Onyx ONE Global Study Also Show Superior Acute Performance and Build Upon Robust Clinical Evidence for Resolute Onyx with Shortened DAPT

DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) announced today late-breaking clinical data from the Onyx ONE Global Study, representing the first...
May 22, 2019

Results Announced from Two Renal Denervation Studies at EuroPCR Show Positive Outcomes in High-Risk Hypertensive Patients

Results Announced from Two Renal Denervation Studies at EuroPCR Show Positive Outcomes in High-Risk Hypertensive Patients

Show per page